Accuray's third quarter told two stories at the same time, and the stock - currently trading at roughly $0.28 a share on the Nasdaq Capital Market, after touching a 52-week high of $1.85 in October 2025 and a 52-week low of $0.23 in late July 2026, and having closed under $1.00 every day since November 2025 - is pricing only one of them. On the surface, the picture is grim: total net revenue fell 7% to $104.8M, GAAP net loss widened to $(11.8)M from $(1.3)M, and management withdrew its full-year FY2026 revenue and Adjusted EBITDA guidance for the first time in the company's recent history, citing Middle East installation delays. Underneath, the company is roughly a third of the way through a self-funded transformation plan that has already pulled out ~$10M of cost and margin improvements, is cutting the workforce by roughly 18% in cumulative terms through June 30, 2026, and is producing a coherent gross-margin repair story - even as gross margin itself dropped 380 basis points to 24.1% in the quarter, weighed down by $3.2M of higher parts consumption and outsized logistics costs. The two narratives cannot both be true at the current share price, and the 180-day Nasdaq Capital Market window to regain a $1.00 bid - which started on August 6, 2026 and runs to February 1, 2027 - is the explicit countdown investors are watching. The thesis is that the transformation is real and the order book is stabilizing; the falsification test is whether Adjusted EBITDA turns sustainably positive in Q4 FY2026 (June 2026), whether order backlog stabilizes near the $356.2M March 31 level, and whether the company regains the $1.00 bid before the Nasdaq deadline expires. At a $33M market capitalization against a $145.2M debt stack and $44.4M of total cash, this is a sub-scale balance sheet trading at a fraction of working capital - and the next twelve weeks of the fiscal year will determine whether the company emerges as a sub-$1 listing casualty or a re-rated medtech turnaround.
All figures are GAAP unless identified as Adjusted EBITDA, a non-GAAP measure; Accuray does not present a non-GAAP adjusted operating income measure - the company's primary non-GAAP profitability anchor is Adjusted EBITDA, reconciled to GAAP net loss in the company's own earnings release.